A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (NCT06283966)
A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)
๐ฉบ Plain-English Summary (8th-Grade Level)
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 ฮผg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 ฮผg in a population with COPD and elevated cardiopulmonary risk.
Who can join: Review the eligibility criteria below.
Location: Research Site โ Athens, Alabama
Age range: 40 Years to 80 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (921 Sites)
Showing the first 25 of 921 sites.
- Research Site โ Athens, Alabama
- Research Site โ Cullman, Alabama
- Research Site โ Fairhope, Alabama
- Research Site โ Huntsville, Alabama
- Research Site โ Mobile, Alabama
- Research Site โ Sheffield, Alabama
- Research Site โ Gilbert, Arizona
- Research Site โ Glendale, Arizona
- Research Site โ Mesa, Arizona
- Research Site โ Mesa, Arizona
- Research Site โ Phoenix, Arizona
- Research Site โ Tempe, Arizona
- Research Site โ Tempe, Arizona
- Research Site โ Tucson, Arizona
- Research Site โ Tucson, Arizona
- Research Site โ Apple Valley, California
- Research Site โ Canoga Park, California
- Research Site โ Castroville, California
- Research Site โ Garden Grove, California
- Research Site โ Gardena, California
- Research Site โ Inglewood, California
- Research Site โ La Mesa, California
- Research Site โ La Palma, California
- Research Site โ Lomita, California
- Research Site โ Long Beach, California
๐ Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COPD (Chronic Obstructive Pulmonary Disease)
- Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD โ Edmonton, Alberta
- Modulating Locomotor-Respiratory Coupling Through Adaptive Exoskeleton Assistance in Patients With COPD โ Omaha, Nebraska
- Development And Evaluation of An Adaptive Web-Based Intervention for COPD โ Aurora, Colorado
- Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia โ Durham, North Carolina
- COPD Exacerbation Follow Up โ Park Ridge, Illinois
- Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD โ San Francisco, California
Explore by condition: All COPD (Chronic Obstructive Pulmonary Disease) clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.